Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$22.17 - $51.8 $421,407 - $984,614
-19,008 Reduced 36.16%
33,564 $1.73 Million
Q2 2022

Aug 15, 2022

BUY
$15.36 - $27.51 $807,505 - $1.45 Million
52,572 New
52,572 $1.3 Million
Q2 2021

Aug 06, 2021

SELL
$9.59 - $50.88 $610,326 - $3.24 Million
-63,642 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$49.53 - $68.4 $2.39 Million - $3.3 Million
48,208 Added 312.35%
63,642 $3.26 Million
Q4 2020

Feb 08, 2021

SELL
$47.25 - $65.16 $1.17 Million - $1.61 Million
-24,756 Reduced 61.6%
15,434 $956,000
Q3 2020

Nov 06, 2020

BUY
$46.35 - $61.69 $1.23 Million - $1.64 Million
26,587 Added 195.45%
40,190 $2.2 Million
Q2 2020

Aug 17, 2020

SELL
$38.58 - $65.07 $367,127 - $619,206
-9,516 Reduced 41.16%
13,603 $783,000
Q2 2020

Aug 11, 2020

BUY
$38.58 - $65.07 $387,227 - $653,107
10,037 Added 76.72%
23,119 $1.08 Million
Q1 2020

May 14, 2020

SELL
$32.73 - $50.78 $570,942 - $885,806
-17,444 Reduced 57.14%
13,082 $526,000
Q4 2019

Feb 06, 2020

SELL
$6.81 - $39.55 $253,733 - $1.47 Million
-37,259 Reduced 54.97%
30,526 $1.21 Million
Q3 2019

Nov 12, 2019

SELL
$6.47 - $8.96 $39,583 - $54,817
-6,118 Reduced 8.28%
67,785 $460,000
Q2 2019

Aug 14, 2019

BUY
$8.31 - $14.85 $27,497 - $49,138
3,309 Added 4.69%
73,903 $684,000
Q1 2019

May 15, 2019

BUY
$10.01 - $13.89 $11,671 - $16,195
1,166 Added 1.68%
70,594 $986,000
Q4 2018

Feb 13, 2019

BUY
$9.15 - $12.26 $21,648 - $29,007
2,366 Added 3.53%
69,428 $868,000
Q3 2018

Nov 08, 2018

BUY
$10.49 - $13.72 $613,801 - $802,798
58,513 Added 684.44%
67,062 $852,000
Q2 2018

Aug 03, 2018

BUY
$10.62 - $13.98 $60,873 - $80,133
5,732 Added 203.48%
8,549 $113,000
Q1 2018

May 11, 2018

BUY
$5.9 - $14.99 $2,808 - $7,135
476 Added 20.33%
2,817 $38,000
Q4 2017

Feb 08, 2018

BUY
$5.53 - $8.42 $66 - $101
12 Added 0.52%
2,341 $14,000
Q3 2017

Nov 06, 2017

BUY
$6.5 - $10.69 $15,138 - $24,897
2,329
2,329 $17,000

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.